Hwang-Phill Kim
Overview
Explore the profile of Hwang-Phill Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin D, Gong J, Jeong S, Cho Y, Kim H, Kim T, et al.
Adv Sci (Weinh)
. 2025 Jan;
12(8):e2412503.
PMID: 39840939
A cell fate change such as tumorigenesis incurs critical transition. It remains a longstanding challenge whether the underlying mechanism can be unraveled and a molecular switch that can reverse such...
2.
Hwang S, Woo S, Kang B, Kang H, Kim J, Lee S, et al.
J Hepatol
. 2024 Oct;
PMID: 39442892
Background & Aims: Recent advances in molecular profiling have enabled the identification of potential therapeutic targets for biliary tract cancer (BTC). However, in patients with BTC, molecular profiling is hindered...
3.
Park S, Baek Y, Lee C, Kim H, Kim H, Jeon Y, et al.
BMC Vet Res
. 2024 May;
20(1):233.
PMID: 38807154
Canine mammary gland tumors (MGT) have a poor prognosis in intact female canines, posing a clinical challenge. This study aimed to establish novel canine mammary cancer cell lines from primary...
4.
Park S, Kang J, Lee N, Lee S, Kim H, Kim S, et al.
Transl Lung Cancer Res
. 2024 Mar;
13(2):280-291.
PMID: 38496698
Background: Limited disease (LD) small cell lung cancer (SCLC) treated with definitive concurrent chemoradiotherapy (CCRT) potentially experience disease recurrence. We investigated the feasibility of circulating-tumor DNA (ctDNA)-based genomic and fragmentome...
5.
Yi H, Youk J, Lim Y, Roh H, Kyung D, Kim H, et al.
Cancer Res Treat
. 2024 Jan;
56(3):765-773.
PMID: 38186238
Purpose: There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)-based circulating tumor DNA...
6.
Kim S, Jeong S, Lee W, Jeon Y, Kim Y, Park S, et al.
Exp Mol Med
. 2023 Nov;
55(11):2445-2460.
PMID: 37907748
Cell-free DNA (cfDNA) sequencing has demonstrated great potential for early cancer detection. However, most large-scale studies have focused only on either targeted methylation sites or whole-genome sequencing, limiting comprehensive analysis...
7.
Lee D, Lee W, Kim H, Kim M, Ahn H, Bang D, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345205
Patients with hematuria are commonly given an invasive cystoscopy test to detect bladder cancer (BC). To avoid the risks associated with cystoscopy, several urine-based methods for BC detection have been...
8.
Jeong S, Kyung D, Yuk H, Jeong C, Lee W, Yoon J, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345184
Traditional tissue-based assessments of genomic alterations in castration-resistant prostate cancer (CRPC) can be challenging. To evaluate the real-world clinical utility of liquid biopsies for the evaluation of genomic alterations in...
9.
Ryoo S, Heo S, Lim Y, Lee W, Cho S, Ahn J, et al.
Br J Cancer
. 2023 Jun;
129(2):374-381.
PMID: 37280413
Background: Postoperative minimal residual disease (MRD) detection using circulating-tumour DNA (ctDNA) requires a highly sensitive analysis platform. We have developed a tumour-informed, hybrid-capture ctDNA sequencing MRD assay. Methods: Personalised target-capture...
10.
Kim S, Cha Y, Lim Y, Roh H, Kang J, Lee K, et al.
Int J Cancer
. 2023 May;
153(3):571-583.
PMID: 37194418
Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging...